GSK Stock Overview
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
GSK plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£39.27 |
| 52 Week High | UK£43.84 |
| 52 Week Low | UK£33.33 |
| Beta | 0.27 |
| 1 Month Change | -7.21% |
| 3 Month Change | -1.03% |
| 1 Year Change | 7.71% |
| 3 Year Change | -16.62% |
| 5 Year Change | -21.89% |
| Change since IPO | -43.27% |
Recent News & Updates
Shareholder Returns
| GSK | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.8% | -2.3% | -3.7% |
| 1Y | 7.7% | 11.4% | 20.2% |
Return vs Industry: GSK underperformed the US Pharmaceuticals industry which returned 11.4% over the past year.
Return vs Market: GSK underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| GSK volatility | |
|---|---|
| GSK Average Weekly Movement | 2.1% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GSK has not had significant price volatility in the past 3 months.
Volatility Over Time: GSK's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 70,212 | Emma Walmsley | www.gsk.com |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.
GSK plc Fundamentals Summary
| GSK fundamental statistics | |
|---|---|
| Market cap | US$80.47b |
| Earnings (TTM) | US$6.13b |
| Revenue (TTM) | US$37.72b |
13.1x
P/E Ratio2.1x
P/S RatioIs GSK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSK income statement (TTM) | |
|---|---|
| Revenue | UK£30.33b |
| Cost of Revenue | UK£8.39b |
| Gross Profit | UK£21.94b |
| Other Expenses | UK£17.01b |
| Earnings | UK£4.93b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | 1.21 |
| Gross Margin | 72.34% |
| Net Profit Margin | 16.25% |
| Debt/Equity Ratio | 131.4% |
How did GSK perform over the long term?
See historical performance and comparison